Medication And Non-Drug Therapy Selection - NAPLEX

A 67-year-old woman (weight 62 kg) with COPD presents to the pharmacy with 2 days of worsening shortness of breath and increased sputum volume and purulence. Medical history: COPD (GOLD group D), hypertension; allergies: none. Current medications: tiotropium inhalation 2 puffs daily, budesonide/formoterol 160/4.5 mcg 2 puffs twice daily, albuterol metered-dose inhaler 2 puffs every 4 hours as needed (using every 2 hours today), amlodipine 5 mg daily. Vitals today: oxygen saturation 90% on room air (baseline 94%), respiratory rate 24/min, heart rate 102/min, temperature 37.9°C. Lifestyle: continues to smoke 1 pack/day. Which medication is most appropriate for managing this patient's condition?
Answer: Start prednisone 40 mg by mouth daily for 5 days and doxycycline 100 mg by mouth twice daily for 5 days This question tests the management of acute exacerbations in chronic obstructive pulmonary disease (COPD). The key patient-specific factor is the presence of increased sputum volume and purulence with low-grade fever, indicating a bacterial exacerbation in a GOLD group D patient. Starting prednisone 40 mg daily for 5 days and doxycycline 100 mg twice daily for 5 days is the best choice as systemic corticosteroids and antibiotics are recommended for moderate to severe COPD exacerbations with purulent sputum. Starting fluticasone nasal spray addresses allergies but not the exacerbation; propranolol may worsen bronchospasm; discontinuing tiotropium and scheduling albuterol ignores the need for steroids and antibiotics. GOLD guidelines emphasize short-course steroids and antibiotics for exacerbations with infection signs to reduce hospitalization risk. Patient-centered care includes smoking cessation counseling and monitoring for antibiotic side effects to improve long-term outcomes.
An 82-year-old man (weight 70 kg) is being discharged after treatment for community-acquired pneumonia and asks the pharmacist to review his medications due to dizziness and near-falls. Medical history: atrial fibrillation, heart failure with reduced ejection fraction, chronic kidney disease stage 3, osteoarthritis; allergies: penicillin (rash). Discharge medications: apixaban 5 mg by mouth twice daily, amiodarone 200 mg by mouth daily, metoprolol succinate 100 mg by mouth daily, furosemide 40 mg by mouth daily, ibuprofen 600 mg by mouth three times daily as needed, and newly prescribed levofloxacin 750 mg by mouth daily for 5 days. Labs/vitals: serum creatinine 1.8 mg/dL (estimated glomerular filtration rate 35 mL/min/1.73 m $^2$ ), potassium 3.3 mEq/L (low), blood pressure 98/62 mmHg, heart rate 56/min. Which therapy modification is necessary given the patient's lab results?
Answer: Hold metoprolol succinate and contact prescriber due to bradycardia/hypotension risk This question tests the identification and modification of therapy in heart failure with reduced ejection fraction (HFrEF) considering drug interactions and vital signs. The key patient-specific factor is bradycardia, hypotension, and dizziness in an elderly patient on multiple negative chronotropic agents like metoprolol, amiodarone, and newly added levofloxacin. Holding metoprolol succinate and contacting the prescriber is necessary to mitigate risks of bradycardia and hypotension. Adding potassium ignores cardiac risks; increasing furosemide may worsen hypotension; adding spironolactone is inappropriate with low potassium and eGFR. ACC/AHA heart failure guidelines emphasize deprescribing in polypharmacy to avoid adverse events. Patient-centered care involves balancing infection treatment with fall prevention and monitoring electrolytes for optimal outcomes.
A 29-year-old woman (weight 95 kg, height 168 cm; body mass index 33.7 kg/m $^2$ ) asks what lifestyle change will most improve her cardiometabolic risk. Medical history: polycystic ovary syndrome; prediabetes; allergies: none. Current medications: ethinyl estradiol/norgestimate 1 tablet daily, metformin 500 mg by mouth twice daily (often misses doses). Labs/vitals: hemoglobin A1c 6.1%, blood pressure 124/82 mmHg. Lifestyle: consumes sweetened coffee drinks daily, minimal vegetables, no structured exercise. What lifestyle change should be recommended as part of the treatment plan?
Answer: Prioritize consistent physical activity (at least 150 minutes/week) and reduce sugar-sweetened beverages as sustainable first steps This question tests lifestyle modifications for cardiometabolic risk in PCOS and prediabetes. The key patient-specific factor is high BMI with sugary drinks and inactivity contributing to insulin resistance. Prioritizing 150 minutes/week activity and reducing sugar-sweetened beverages is sustainable per ADA guidelines for risk reduction. Avoiding all fats is misguided; detox teas lack evidence; skipping meals ignores calories. Guidelines support activity and diet for prevention. Patient-centered care emphasizes vegetable intake and medication adherence for hormonal balance.
A 45-year-old woman (weight 74 kg) reports new persistent dry cough that began 3 weeks after starting a new blood pressure medication. Medical history: hypertension; allergies: none. Current medications: lisinopril 20 mg by mouth daily (started 1 month ago), acetaminophen 650 mg every 6 hours as needed. Vitals/labs: blood pressure 128/78 mmHg, heart rate 72/min, serum creatinine 0.8 mg/dL, potassium 4.5 mEq/L. Lifestyle: non-smoker, no asthma history. Which action should the pharmacist take to address the patient's adverse reaction?
Answer: Recommend switching lisinopril to losartan 50 mg by mouth daily This question tests the management of adverse effects from antihypertensive medications, specifically ACE inhibitor-induced cough. The key patient-specific factor is the new persistent dry cough starting after lisinopril initiation, with controlled blood pressure and no other respiratory issues. Switching lisinopril to losartan 50 mg daily is the best choice as ARBs do not cause cough and provide equivalent antihypertensive efficacy. Adding dextromethorphan continues the offending agent; aliskiren is not preferred due to similar mechanism; increasing lisinopril may worsen cough. ACC/AHA guidelines recommend ARBs as alternatives for ACE inhibitor intolerance. Patient-centered care includes monitoring for resolution of symptoms and blood pressure control to prevent long-term complications.
A 64-year-old woman (weight 68 kg) reports muscle pain and weakness that began after starting simvastatin 40 mg nightly 2 months ago. Medical history: hyperlipidemia, hypothyroidism (controlled); allergies: none. Current medications: simvastatin 40 mg nightly, levothyroxine 75 mcg daily, amlodipine 10 mg daily. Labs: creatine kinase 520 units/L (elevated; normal <200), thyroid-stimulating hormone 2.1 mIU/L, alanine aminotransferase 28 units/L. Lifestyle: drinks grapefruit juice daily. Which action should the pharmacist take to address the patient's adverse reaction?
Answer: Stop simvastatin and switch to pravastatin 40 mg by mouth nightly; avoid grapefruit juice This question tests the management of statin-induced myopathy. The key patient-specific factor is elevated creatine kinase with muscle pain and grapefruit juice consumption, which increases simvastatin exposure. Stopping simvastatin and switching to pravastatin 40 mg nightly while avoiding grapefruit is best as pravastatin has lower interaction risk and equivalent efficacy. Continuing with coenzyme Q10 does not address the cause; increasing simvastatin worsens risk; adding gemfibrozil increases myopathy risk. ACC/AHA guidelines recommend switching statins for intolerance. Patient-centered care involves lifestyle adjustments and monitoring symptoms for safe lipid management.
A 63-year-old man (weight 80 kg) with chronic atrial fibrillation is newly prescribed trimethoprim/sulfamethoxazole for cellulitis. Medical history: atrial fibrillation, hypertension; allergies: none. Current medications: warfarin 5 mg by mouth daily (international normalized ratio goal 2–3; last international normalized ratio 2.4 one week ago), diltiazem ER 240 mg by mouth daily, hydrochlorothiazide 25 mg by mouth daily. Labs today: international normalized ratio 2.5, serum creatinine 1.0 mg/dL; blood pressure 130/76 mmHg. Lifestyle: consistent vitamin K intake, no alcohol. What is the best approach to manage this drug interaction?
Answer: Arrange earlier international normalized ratio monitoring (within 3–5 days) and anticipate warfarin dose reduction during therapy This question tests management of a significant drug interaction between warfarin and trimethoprim/sulfamethoxazole. The key patient-specific factor is the need for antibiotic therapy in a stable warfarin patient, where TMP/SMX inhibits warfarin metabolism and can dramatically increase INR. Arranging early INR monitoring with anticipated dose reduction is optimal because this interaction typically increases INR by 1.5-2 points within 3-5 days. Continuing unchanged (A) risks dangerous supratherapeutic INR and bleeding. Holding warfarin completely (B) may lead to subtherapeutic anticoagulation and stroke risk. Adding aspirin (D) increases bleeding risk without addressing the interaction. The clinical framework for managing warfarin interactions includes early monitoring, preemptive dose adjustments for known significant interactions, and close follow-up, with TMP/SMX being one of the highest-risk antibiotics requiring proactive management.
A 66-year-old woman (weight 62 kg) with COPD presents to the pharmacy with 2 days of worsening shortness of breath, increased sputum volume, and purulent sputum. Medical history: COPD (GOLD group D), hypertension; allergies: penicillin (anaphylaxis). Current medications: tiotropium Respimat 2 inhalations daily, budesonide/formoterol 160/4.5 mcg 2 inhalations twice daily, albuterol metered-dose inhaler 2 inhalations every 4–6 hours as needed (using every 2 hours today), lisinopril 20 mg daily. Vitals at urgent care earlier today: blood pressure 138/84 mmHg, heart rate 104 beats/min, respiratory rate 24/min, oxygen saturation 90% on room air, temperature 38.1°C; no pneumonia on chest X-ray. Lifestyle: continues to smoke 1 pack/day. Which medication is most appropriate for managing this patient's condition?
Answer: Start prednisone 40 mg by mouth daily for 5 days and azithromycin 500 mg once then 250 mg daily for 4 days This question evaluates treatment selection for an acute COPD exacerbation with evidence of bacterial infection. The key patient-specific factors are purulent sputum, fever, and penicillin allergy requiring alternative antibiotic selection. The combination of prednisone and azithromycin is optimal because systemic corticosteroids reduce treatment failure and hospital admissions in COPD exacerbations, while azithromycin covers typical respiratory pathogens. Oseltamivir (B) treats influenza, not bacterial infections or COPD exacerbations. Starting fluticasone/salmeterol (C) during an acute exacerbation is inappropriate as maintenance therapy changes should occur when stable. Amoxicillin/clavulanate (D) is contraindicated due to penicillin allergy, and omitting corticosteroids reduces treatment effectiveness. The clinical framework emphasizes that moderate-to-severe COPD exacerbations require both systemic corticosteroids (typically 40 mg prednisone for 5 days) and antibiotics when bacterial infection is suspected, with antibiotic selection guided by local resistance patterns and patient allergies.
A 58-year-old woman (weight 92 kg) with type 2 diabetes mellitus and hypertension returns for follow-up. Medical history: hypertension, diabetes; allergies: none. Current medications: metformin 1000 mg by mouth twice daily, insulin glargine 20 units subcutaneously nightly, losartan 100 mg by mouth daily, amlodipine 10 mg by mouth daily. Vitals/labs: blood pressure 164/96 mmHg, heart rate 80/min, hemoglobin A1c 7.8%, serum creatinine 1.3 mg/dL (estimated glomerular filtration rate 52 mL/min/1.73 m $^2$ ), potassium 4.6 mEq/L. Lifestyle: reports frequent NSAID use for headaches and high-sodium snacks. Which therapy modification is necessary given the patient's lab results?
Answer: Add chlorthalidone 12.5 mg by mouth daily and counsel to limit NSAIDs and sodium This question tests optimization of antihypertensive therapy in T2DM with uncontrolled blood pressure. The key patient-specific factor is elevated blood pressure with frequent NSAID use and high-sodium diet, which can antagonize therapy. Adding chlorthalidone 12.5 mg daily and counseling on NSAIDs/sodium is necessary for better diuretic efficacy and blood pressure control. Spironolactone risks hyperkalemia with eGFR 52; switching to lisinopril duplicates class; increasing amlodipine exceeds maximum dose. ACC/AHA guidelines recommend thiazide-like diuretics as add-ons. Patient-centered care addresses lifestyle to enhance therapy outcomes and reduce complications.
A 50-year-old man (weight 110 kg, height 180 cm) with obesity and hypertension asks what to focus on first to improve blood pressure without adding medications. Medical history: hypertension; allergies: none. Current medications: amlodipine 10 mg daily. Vitals/labs: blood pressure 148/90 mmHg, heart rate 76/min, serum creatinine 1.0 mg/dL, potassium 4.0 mEq/L. Lifestyle: eats restaurant meals most days, estimated sodium intake >4 g/day, drinks 3 beers nightly, no regular exercise. What non-drug intervention should be prioritized for this patient?
Answer: Adopt a Dietary Approaches to Stop Hypertension (DASH)-style eating pattern and reduce sodium to <2.3 g/day This question tests non-pharmacologic interventions for hypertension in obesity. The key patient-specific factor is high sodium intake and alcohol consumption contributing to uncontrolled blood pressure. Adopting a DASH-style diet and reducing sodium to <2.3 g/day is prioritized as it effectively lowers blood pressure per ACC/AHA guidelines. Increasing protein while avoiding vegetables risks hyperkalemia; intermittent fasting ignores key factors; decongestants may raise blood pressure. Guidelines emphasize dietary sodium reduction for hypertension management. Patient-centered care integrates exercise and alcohol moderation for sustainable blood pressure control and cardiovascular health.
A 29-year-old woman (weight 60 kg) calls the pharmacy reporting frequent wheezing and nighttime awakenings from asthma over the past month. Medical history: asthma; allergic rhinitis; allergies: none. Current medications: albuterol metered-dose inhaler 2 inhalations every 4–6 hours as needed (using 4–5 days/week), montelukast 10 mg by mouth nightly, fluticasone nasal spray 1 spray per nostril daily. Peak flow in clinic is 75% of personal best; oxygen saturation 98% on room air; blood pressure 112/70 mmHg. Lifestyle: lives with a cat, no tobacco use. Which medication is most appropriate for managing this patient's condition?
Answer: Add low-dose inhaled corticosteroid such as budesonide 200 mcg inhaled twice daily This question addresses step-up therapy for uncontrolled asthma. The key patient-specific factor is persistent symptoms despite as-needed bronchodilator use 4-5 days/week, indicating the need for daily controller therapy. Adding a low-dose inhaled corticosteroid like budesonide is the best choice because ICS are the most effective anti-inflammatory controllers for asthma, reducing symptoms, exacerbations, and improving lung function. Salmeterol monotherapy (B) is contraindicated as LABA monotherapy increases asthma mortality risk. Replacing albuterol with ipratropium (C) removes rescue therapy without addressing underlying inflammation. Chronic oral prednisone (D) has significant adverse effects and is reserved for severe asthma unresponsive to inhaled therapy. The clinical framework emphasizes that patients using rescue inhalers more than twice weekly need daily controller therapy, with low-dose ICS as first-line treatment providing optimal benefit-risk ratio for mild persistent asthma.
A 38-year-old woman (weight 102 kg, height 165 cm; body mass index 37.5 kg/m $^2$ ) presents asking for help with weight loss. Medical history: prediabetes; allergies: none. Current medications: none. Labs/vitals: hemoglobin A1c 6.0%, blood pressure 126/80 mmHg, fasting glucose 112 mg/dL, low-density lipoprotein cholesterol 132 mg/dL. Lifestyle: sedentary desk job, eats fast food 5 times/week, drinks alcohol 2–3 drinks nightly, sleeps 5 hours/night. What lifestyle change should be recommended as part of the treatment plan?
Answer: Begin a structured program targeting at least 150 minutes/week of moderate-intensity activity plus calorie reduction (500–750 kcal/day deficit) This question tests lifestyle interventions for weight management in patients with prediabetes and obesity. The key patient-specific factor is the high BMI of 37.5 kg/m² with sedentary lifestyle and poor diet contributing to prediabetes. Beginning a structured program with 150 minutes/week of moderate activity and 500–750 kcal/day deficit is the best choice as it aligns with evidence-based weight loss strategies to prevent diabetes progression. Eliminating all carbohydrates is unsustainable; high-intensity exercise without diet ignores caloric balance; stimulant laxatives are unsafe. ADA guidelines recommend lifestyle changes targeting 5–7% weight loss for prediabetes. Patient-centered care focuses on sustainable habits like reducing alcohol and improving sleep for long-term metabolic health.
A 55-year-old man (weight 100 kg) with type 2 diabetes mellitus and hypertension comes for follow-up after labs. Medical history: diabetes, hypertension, albuminuria; allergies: none. Current medications: metformin 1000 mg by mouth twice daily, dulaglutide 1.5 mg subcutaneously weekly, losartan 100 mg by mouth daily, chlorthalidone 25 mg by mouth daily. Labs/vitals: blood pressure 142/88 mmHg, hemoglobin A1c 7.2%, serum creatinine 1.6 mg/dL (estimated glomerular filtration rate 48 mL/min/1.73 m $^2$ ), potassium 5.6 mEq/L (high). Lifestyle: uses salt substitute frequently; eats high-potassium foods. Which therapy modification is necessary given the patient's lab results?
Answer: Counsel to stop potassium-containing salt substitutes and contact prescriber to evaluate hyperkalemia while continuing losartan This question tests the selection of appropriate therapy modifications in a patient with hypertension, type 2 diabetes, chronic kidney disease (CKD), and hyperkalemia while on an angiotensin receptor blocker (ARB). The key patient-specific factors influencing therapy choice are the elevated serum potassium of 5.6 mEq/L, frequent use of potassium-containing salt substitutes, high-potassium diet, reduced eGFR of 48 mL/min/1.73 m², and ongoing losartan therapy. Counseling the patient to stop potassium-containing salt substitutes and contacting the prescriber to evaluate hyperkalemia while continuing losartan is the best choice because it addresses a modifiable dietary contributor to hyperkalemia without discontinuing the ARB, which provides renal protection in diabetic nephropathy. Adding spironolactone is incorrect as it is a potassium-sparing diuretic that would exacerbate hyperkalemia, and increasing losartan to 200 mg daily is suboptimal because it exceeds the maximum recommended dose of 100 mg and could worsen hyperkalemia. Adding potassium chloride is inappropriate and dangerous given the existing hyperkalemia, despite chlorthalidone's potential to cause hypokalemia, as the net effect here is elevated potassium. A key clinical pearl is that guidelines from the American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend ARBs like losartan for patients with diabetes, albuminuria, and CKD to slow disease progression, but regular monitoring of potassium and patient education on low-potassium diets are essential for safety. This patient-centered approach balances evidence-based renoprotection with minimizing risks like hyperkalemia, potentially improving long-term outcomes such as reduced albuminuria and preserved renal function.
A 69-year-old woman (weight 66 kg) with COPD presents with acute worsening dyspnea and wheezing for 24 hours after a viral upper respiratory infection; she denies increased sputum purulence. Medical history: COPD; osteoporosis; allergies: none. Current medications: tiotropium inhalation daily, albuterol inhaler as needed, alendronate 70 mg weekly, calcium/vitamin D daily. Vitals: oxygen saturation 91% on room air, respiratory rate 20/min, temperature 37.2°C. Lifestyle: former smoker; adherent to maintenance inhaler. Which medication is most appropriate for managing this patient's condition?
Answer: Start prednisone 40 mg by mouth daily for 5 days This question tests management of non-infectious COPD exacerbations. The key patient-specific factor is acute dyspnea post-viral infection without purulence, in a patient with osteoporosis. Starting prednisone 40 mg daily for 5 days is best as short-course systemic corticosteroids are recommended for acute exacerbations per GOLD guidelines. Amoxicillin is unnecessary without infection; fluticasone nasal is for rhinitis; theophylline is not first-line due to toxicity. Guidelines aim to reduce symptoms and relapse. Patient-centered care considers osteoporosis risk with steroids and promotes adherence for better control.
A 52-year-old man (weight 86 kg) presents for preventive care and asks whether he should start a cholesterol medication. Medical history: hypertension; no diabetes; no clinical atherosclerotic cardiovascular disease. Allergies: none. Current medications: chlorthalidone 25 mg by mouth daily. Vitals/labs: blood pressure 136/84 mmHg, total cholesterol 228 mg/dL, low-density lipoprotein cholesterol 154 mg/dL, high-density lipoprotein cholesterol 38 mg/dL, triglycerides 180 mg/dL, serum creatinine 0.9 mg/dL; 10-year ASCVD risk estimated at 12%. Lifestyle: smokes 0.5 pack/day, diet high in saturated fat, minimal exercise. Which medication is most appropriate for managing this patient's condition?
Answer: Start atorvastatin 40 mg by mouth nightly This question tests lipid-lowering therapy selection in primary prevention for patients with elevated ASCVD risk. The key patient-specific factor is the 10-year ASCVD risk of 12% with hypertension, smoking, and dyslipidemia. Starting atorvastatin 40 mg nightly is the best choice as moderate- to high-intensity statins are recommended for adults aged 40–75 with ≥7.5% ASCVD risk per ACC/AHA guidelines. Fenofibrate and niacin are not first-line for LDL-C reduction in this context; ezetimibe monotherapy is suboptimal without statin intolerance. ACC/AHA guidelines prioritize statins for primary prevention to reduce cardiovascular events. Patient-centered care involves lifestyle modifications like smoking cessation and diet changes alongside statin therapy for optimal risk reduction.
A 57-year-old woman (weight 60 kg) complains of flushing and itching after starting immediate-release niacin 500 mg three times daily for cholesterol 1 week ago. Medical history: dyslipidemia; allergies: none. Current medications: niacin immediate-release 500 mg three times daily (self-started), atorvastatin 20 mg nightly. Labs: alanine aminotransferase 32 units/L, fasting glucose 108 mg/dL, uric acid 8.2 mg/dL (high). Lifestyle: drinks wine nightly. Which action should the pharmacist take to address the patient's adverse reaction?
Answer: Recommend discontinuing niacin and optimizing statin therapy instead This question tests management of niacin adverse effects in dyslipidemia. The key patient-specific factor is flushing with immediate-release niacin, elevated uric acid, and concurrent statin use. Recommending discontinuation of niacin and optimizing statin is best as niacin adds limited benefit and significant side effects per guidelines. Doubling dose worsens flushing; adding allopurinol treats symptomatically; switching to gemfibrozil increases myopathy risk. ACC/AHA guidelines de-emphasize niacin due to risks. Patient-centered care focuses on alcohol reduction and statin titration for effective lipid control.
A 48-year-old man (weight 92 kg) presents for preventive care. Medical history: hypertension; chronic kidney disease stage 2; no diabetes; allergies: none. Current medications: valsartan 160 mg by mouth daily. Labs/vitals: blood pressure 128/78 mmHg, low-density lipoprotein cholesterol 190 mg/dL, triglycerides 140 mg/dL, serum creatinine 1.2 mg/dL (estimated glomerular filtration rate 68 mL/min/1.73 m $^2$ ), alanine aminotransferase 22 units/L. Lifestyle: non-smoker; exercises 1 time/week. Which medication is most appropriate for managing this patient's condition?
Answer: Start atorvastatin 80 mg by mouth nightly This question tests lipid management in patients with hypertension and CKD. The key patient-specific factor is LDL-C 190 mg/dL with CKD stage 2, warranting high-intensity statin for risk reduction. Starting atorvastatin 80 mg nightly is appropriate as high-intensity statins are recommended for high-risk patients per ACC/AHA guidelines. Ezetimibe monotherapy is insufficient; fenofibrate targets triglycerides; no therapy ignores risk. Guidelines emphasize statins in CKD for cardiovascular protection. Patient-centered care includes exercise promotion and liver monitoring for safety.
An 82-year-old man (weight 74 kg) is discharged after a fall and brings his medication bottles for reconciliation. Medical history: atrial fibrillation, heart failure with reduced ejection fraction, osteoarthritis, chronic kidney disease stage 3; allergies: none. Current medications listed: warfarin (variable dosing; last international normalized ratio 2.6), amiodarone 200 mg by mouth daily, carvedilol 12.5 mg by mouth twice daily, lisinopril 10 mg by mouth daily, furosemide 40 mg by mouth daily, spironolactone 25 mg by mouth daily, ibuprofen 600 mg by mouth three times daily for knee pain, acetaminophen 500 mg by mouth as needed. Labs: serum creatinine 1.8 mg/dL (estimated glomerular filtration rate 35 mL/min/1.73 m $^2$ ), potassium 5.6 mEq/L (high; normal 3.5–5.0), blood pressure 118/70 mmHg. Lifestyle: limited mobility, drinks 1–2 glasses of wine nightly. Which therapy modification is necessary given the patient's lab results?
Answer: Discontinue spironolactone and reassess potassium and renal function within 3–7 days This question tests recognition and management of drug-induced hyperkalemia in a complex elderly patient. The key patient-specific factors are hyperkalemia (5.6 mEq/L), concurrent use of multiple potassium-increasing drugs (lisinopril, spironolactone), and NSAID use with reduced renal function. Discontinuing spironolactone is the best initial step because it directly increases potassium, and the combination with ACE inhibitor and NSAIDs creates dangerous synergy. Increasing spironolactone (A) would worsen hyperkalemia and risk cardiac arrhythmias. Adding potassium supplements (C) is contraindicated with existing hyperkalemia. Continuing current therapy (D) ignores a potentially life-threatening electrolyte abnormality requiring prompt intervention. The clinical pearl is that hyperkalemia risk increases exponentially when combining RAS inhibitors, potassium-sparing diuretics, and NSAIDs, especially in elderly patients with reduced renal function, requiring careful monitoring and often medication discontinuation to prevent cardiac complications.
A 44-year-old woman (weight 70 kg) reports new persistent dry cough that began 3 weeks after starting a new blood pressure medication. Medical history: hypertension; seasonal allergic rhinitis; allergies: none. Current medications: lisinopril 20 mg by mouth daily (started 1 month ago), cetirizine 10 mg by mouth daily as needed, ibuprofen 200 mg by mouth as needed for headache. Vitals today: blood pressure 132/78 mmHg, heart rate 76 beats/min; labs: serum creatinine 0.8 mg/dL, potassium 4.2 mEq/L; pregnancy test negative. Lifestyle: non-smoker, runs 2–3 times/week. Which action should the pharmacist take to address the patient's adverse reaction?
Answer: Switch lisinopril to losartan 50 mg by mouth daily This question addresses management of ACE inhibitor-induced cough, a common adverse effect. The key patient-specific factor is the temporal relationship between lisinopril initiation and cough onset, with good blood pressure control on current therapy. Switching to losartan, an ARB, is the best approach because ARBs provide similar cardiovascular and renal benefits without causing cough (incidence <1% vs 5-10% with ACE inhibitors). Adding dextromethorphan (A) treats symptoms but doesn't address the underlying cause and cough will persist. Aliskiren (C) is less studied, more expensive, and not preferred over ARBs for this indication. Stopping lisinopril without replacement therapy (D) leaves hypertension untreated and lacks appropriate monitoring. The clinical framework emphasizes that ACE inhibitor cough is class-related, dry, persistent, and resolves within 1-4 weeks of discontinuation, with ARBs being the preferred alternative for patients requiring RAS blockade.
A 56-year-old man (weight 98 kg, height 178 cm) presents for chronic disease follow-up because his home blood glucose readings have been increasing. Medical history includes type 2 diabetes mellitus, hypertension, and hyperlipidemia; allergies: lisinopril (angioedema). Current medications: metformin extended-release 1000 mg by mouth twice daily, amlodipine 10 mg by mouth daily, hydrochlorothiazide 25 mg by mouth daily, atorvastatin 40 mg by mouth nightly. Vitals/labs: blood pressure 152/94 mmHg (average of 3 readings), heart rate 78 beats/min, hemoglobin A1c 8.6%, serum creatinine 1.0 mg/dL (estimated glomerular filtration rate 88 mL/min/1.73 m $^2$ ), potassium 4.2 mEq/L. Lifestyle: sedentary, diet high in refined carbohydrates, drinks 2 sugar-sweetened sodas daily, never smoker. Which medication is most appropriate for managing this patient's condition?
Answer: Start losartan 50 mg by mouth daily This question tests the selection of antihypertensive therapy in a patient with type 2 diabetes mellitus (T2DM) and uncontrolled hypertension. The key patient-specific factor is the history of angioedema with lisinopril, which contraindicates ACE inhibitors, alongside elevated blood pressure and hemoglobin A1c. Starting losartan 50 mg daily is the best choice because ARBs are recommended as first-line agents for hypertension in T2DM for their renal protective effects and are safe alternatives to ACE inhibitors in patients with angioedema history. Adding sitagliptin addresses hyperglycemia but does not target the uncontrolled hypertension or provide cardioprotection; starting lisinopril is contraindicated due to allergy; increasing hydrochlorothiazide may worsen hyperglycemia and is not preferred over adding an ARB. According to ACC/AHA guidelines, ARBs should be prioritized in T2DM with hypertension for blood pressure control and renal protection. Patient-centered care involves considering allergies, lifestyle factors like diet, and potential outcomes such as reduced cardiovascular risk with ARB therapy.
A 52-year-old man (weight 86 kg, height 175 cm) presents for preventive care and asks whether he should start a cholesterol medication. Medical history: type 2 diabetes (diagnosed 3 years ago), no known atherosclerotic cardiovascular disease; allergies: none. Current medications: metformin 1000 mg by mouth twice daily, semaglutide 0.5 mg subcutaneously weekly. Labs: low-density lipoprotein cholesterol 142 mg/dL, high-density lipoprotein cholesterol 38 mg/dL, triglycerides 210 mg/dL, alanine aminotransferase 28 units/L, serum creatinine 0.9 mg/dL; blood pressure averages 128/78 mmHg. Lifestyle: sedentary, diet high in saturated fat, drinks alcohol socially, never smoker. Which medication is most appropriate for managing this patient's condition?
Answer: Start atorvastatin 40 mg by mouth nightly This question tests primary prevention statin therapy selection in a diabetic patient. The key patient-specific factor is diabetes mellitus in a patient aged 40-75 years, which automatically qualifies him for moderate-to-high intensity statin therapy regardless of calculated ASCVD risk. Atorvastatin 40 mg is the best choice as it provides high-intensity therapy appropriate for diabetic patients with additional risk factors (low HDL, elevated triglycerides). Fenofibrate monotherapy (B) primarily targets triglycerides but lacks the robust cardiovascular outcome data of statins. Ezetimibe monotherapy (C) is less effective than statins for primary prevention. Deferring therapy (D) is incorrect because diabetes alone warrants statin initiation in this age group. The clinical pearl is that all diabetic patients aged 40-75 should receive at least moderate-intensity statin therapy, with high-intensity statins preferred when additional ASCVD risk factors are present, following ACC/AHA cholesterol guidelines.

Start this quiz